Context Therapeutics (CNTX) EBITDA (2020 - 2026)

Context Therapeutics has disclosed EBITDA across 7 years of filings, most recently posting -$9.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$9.3 million, down 68.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$43.5 million (down 37.58% YoY), and the FY2025 annual result was -$39.7 million, down 32.68% from the prior year.
• EBITDA came in at -$9.3 million for Q1 2026 at Context Therapeutics, up from -$13.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.1 million in Q2 2024 to a low of -$18.7 million in Q3 2024.
• The 5-year median for EBITDA is -$5.5 million (2025), against an average of -$7.0 million.
• Across the five-year window, EBITDA slumped 309.72% in 2022 and jumped 43.26% in 2025, its largest moves.
• Context Therapeutics' EBITDA stood at -$3.9 million in 2022, then plunged by 78.58% to -$6.9 million in 2023, then soared by 37.83% to -$4.3 million in 2024, then tumbled by 220.26% to -$13.8 million in 2025, then soared by 32.31% to -$9.3 million in 2026.
• The last three EBITDA figures came in at -$9.3 million (Q1 2026), -$13.8 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.